BioSpace News Archive

aTyr Pharma, Inc. today announced multiple presentations at the International Union of Biochemistry and Molecular Biology’s 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023), which is scheduled to take place June 4 – 9 in Ontario, Canada.

Bionano Genomics, Inc. announced the commercial release of new kits for its Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded and tumor tissue.

AccuStem Sciences, Inc., a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced the establishment of a joint clinical collaboration agreement with University Hospitals.

Brain–computer interface company Precision Neuroscience Corporation announced that the first-in-human procedures in a pilot clinical study of its neural implant system have been successfully completed.

Zentalis® Pharmaceuticals, Inc. announced the monotherapy recommended Phase 2 dose for azenosertib, the Company’s potentially first-in-class WEE1 inhibitor.

Micropep Technologies, the global leader in micropeptide technology, announced the appointment of Dr. Kevin Leiner as its new Head of Regulatory and Head of Development Americas.

BrainStorm Cell Therapeutics Inc. announced that the U.S. Food and Drug Administration will convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to review the Biologics License Application for NurOwn®, its investigational mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis.

ANEW MEDICAL, INC., an early-stage biotechnology company focused on developing disruptive new therapies to treat age-related neurodegenerative diseases, previously announced that it has entered into a definitive business combination agreement with Redwoods Acquisition Corp., a publicly traded special purpose acquisition company, or SPAC.

Vyluma, Inc. (“Vyluma”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead compound, NVK002 (low dose atropine 0.01%) as a potential treatment for myopia in children.

Algernon Pharmaceuticals Inc. is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9 th American Cough Conference (ACC) being held June 9-10, 2023 in Reston, Virginia.